Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryosurgery | 3 | 2024 | 197 | 2.330 |
Why?
|
| Printing, Three-Dimensional | 4 | 2024 | 144 | 1.580 |
Why?
|
| Breast Neoplasms | 26 | 2024 | 16246 | 1.560 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 2 | 2024 | 106 | 1.400 |
Why?
|
| Patient Positioning | 1 | 2024 | 196 | 0.790 |
Why?
|
| Mastectomy, Segmental | 4 | 2023 | 1050 | 0.790 |
Why?
|
| Mastectomy | 4 | 2023 | 1554 | 0.720 |
Why?
|
| Spinal Neoplasms | 1 | 2024 | 671 | 0.610 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2022 | 1385 | 0.600 |
Why?
|
| Patient Participation | 1 | 2021 | 454 | 0.550 |
Why?
|
| Mammography | 10 | 2021 | 1055 | 0.530 |
Why?
|
| Image-Guided Biopsy | 5 | 2018 | 336 | 0.520 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 603 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 7923 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 557 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 1225 | 0.420 |
Why?
|
| Palliative Care | 1 | 2024 | 2177 | 0.410 |
Why?
|
| Ultrasonography, Mammary | 5 | 2021 | 387 | 0.390 |
Why?
|
| Calcinosis | 4 | 2021 | 427 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 10 | 2024 | 5247 | 0.350 |
Why?
|
| Quality of Life | 1 | 2024 | 4810 | 0.330 |
Why?
|
| Female | 30 | 2024 | 148936 | 0.260 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 690 | 0.240 |
Why?
|
| Breast | 4 | 2019 | 1370 | 0.230 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 14037 | 0.230 |
Why?
|
| Prone Position | 1 | 2024 | 60 | 0.220 |
Why?
|
| Carcinoma, Lobular | 2 | 2021 | 622 | 0.220 |
Why?
|
| Contrast Media | 3 | 2020 | 1505 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2021 | 1235 | 0.210 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 1828 | 0.200 |
Why?
|
| Humans | 31 | 2024 | 270804 | 0.200 |
Why?
|
| Ultrasonography | 4 | 2021 | 1932 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2024 | 425 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2020 | 1464 | 0.190 |
Why?
|
| Middle Aged | 17 | 2024 | 90569 | 0.180 |
Why?
|
| Fasciitis | 1 | 2020 | 39 | 0.180 |
Why?
|
| Prognosis | 6 | 2021 | 22533 | 0.180 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 27 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 551 | 0.170 |
Why?
|
| Feasibility Studies | 3 | 2021 | 2360 | 0.170 |
Why?
|
| Epigastric Arteries | 1 | 2020 | 45 | 0.170 |
Why?
|
| Margins of Excision | 2 | 2019 | 315 | 0.170 |
Why?
|
| Adult | 16 | 2024 | 82073 | 0.170 |
Why?
|
| Aged | 13 | 2024 | 73640 | 0.150 |
Why?
|
| Perforator Flap | 1 | 2020 | 96 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2022 | 13422 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 247 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2024 | 39982 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2020 | 3081 | 0.140 |
Why?
|
| Neoplasm Seeding | 1 | 2017 | 66 | 0.140 |
Why?
|
| Fiducial Markers | 1 | 2016 | 95 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 432 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 1175 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 165 | 0.120 |
Why?
|
| Patient Preference | 1 | 2017 | 231 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 294 | 0.120 |
Why?
|
| Axilla | 4 | 2020 | 945 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2017 | 553 | 0.110 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 241 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 854 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 930 | 0.110 |
Why?
|
| Mass Screening | 2 | 2011 | 1547 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 15280 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2020 | 714 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3429 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 601 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2024 | 33859 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 31117 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 4470 | 0.090 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 10731 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2011 | 200 | 0.080 |
Why?
|
| Sarcoma | 1 | 2020 | 1851 | 0.080 |
Why?
|
| Biopsy | 1 | 2017 | 3490 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 411 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 339 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 2068 | 0.070 |
Why?
|
| Time Factors | 2 | 2017 | 12979 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1330 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 4007 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14639 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5606 | 0.050 |
Why?
|
| Risk Factors | 1 | 2017 | 17867 | 0.040 |
Why?
|
| Dissection | 1 | 2020 | 134 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2021 | 339 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 591 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 4969 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 1019 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 139 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 182 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1033 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 291 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 2033 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 388 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 690 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 1345 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 5157 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3054 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4966 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 22255 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 4839 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 1342 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 16751 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 688 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 709 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1761 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1381 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1308 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6193 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 1061 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5924 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 9047 | 0.010 |
Why?
|
| United States | 1 | 2017 | 15834 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 32698 | 0.010 |
Why?
|